Bayer Can Briefly Stop Rivals Selling Patented Xarelto Dosage
Bayer AG can briefly block its rivals from selling generic versions of anticoagulant Xarelto at its protected once-daily dosage while both sides await a ruling on the validity of the patent,...To view the full article, register now.
Already a subscriber? Click here to view full article